MedTrace Logo

A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above

NCT07204964 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 971

Last updated 2026-03-27

No results posted yet for this study

Summary

The purpose of this study is to assess the reactogenicity, safety and immune response of GlaxoSmithKline's (GSK) messenger RNA (mRNA)-based multivalent seasonal influenza vaccine candidates administered in healthy younger and older adults.

Conditions

  • Influenza, Human

Interventions

BIOLOGICAL

Flu mRNA (Formulation B1)

One dose of Flu mRNA (Formulation B1) received intramuscularly.

BIOLOGICAL

Flu mRNA (Formulation B3)

One dose of Flu mRNA (Formulation B3) received intramuscularly.

BIOLOGICAL

Flu mRNA(Formulation A)

One dose of Flu mRNA (Formulation A) received intramuscularly.

COMBINATION_PRODUCT

Comparator 1

One dose of Comparator 1 received intramuscularly.

COMBINATION_PRODUCT

Comparator 2

One dose of Comparator 2 received intramuscularly.

COMBINATION_PRODUCT

Comparator 3

One dose of Comparator 3 received intramuscularly.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-10-07
Primary Completion
2026-07-31
Completion
2026-07-31
FDA Drug
Yes

Countries

  • United States
  • Belgium

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07204964 on ClinicalTrials.gov